enGene Holdings ( (ENGN) ) has provided an update.
enGene Holdings Inc. has released promising preliminary data from its LEGEND study, showing a 71% complete response rate in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer treated with their investigational product, detalimogene voraplasmid. The treatment was well-tolerated, with no treatment-related discontinuations, and the company is planning to refine the study protocol to further benefit patients. The early results suggest detalimogene could be an effective and practical therapy in both clinical and community practice settings, with the potential to become a foundational treatment for this common form of bladder cancer.
See more data about ENGN stock on TipRanks’ Stock Analysis page.
